SCHEMBL18153355

SCHEMBL18153355

Cc1ccc(Nc2cc(N3CCOCC3)nc(N3CCNCC3)n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.69
MAPT P10636 3/20 0.69
SMN1; SMN2 Q16637 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
BPTF Q12830 1/20 0.55
MAPK1 P28482 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
POLB P06746 2/20 0.53
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 2/20 0.52
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 4/20 0.49
HPGD P15428 2/20 0.49
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 1/20 0.48
ROCK2 O75116 1/20 0.48
GAA P10253 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18153416 0.90 CASP1 (0.61) LMNAMAPTBPTFNPSR1ALDH1A1
SCHEMBL3246321 0.88 CASP1 (0.59) LMNAMAPTSMN1; SMN2BPTFALDH1A1
SCHEMBL18063516 0.82 LMNA (0.72) LMNAMAPTBPTFMAPK1TAAR1
SCHEMBL3245932 0.80 GALR2 (0.61) LMNAMAPTSMN1; SMN2NPSR1GAA
SCHEMBL18153318 0.80 BPTF (0.65) LMNAMAPTBPTFROCK2CASP1
SCHEMBL9069830 0.80 CASP1 (0.71) SMN1; SMN2POLBNPSR1KMT2AKDM4E
SCHEMBL23321038 0.80 MAPT (0.77) LMNAMAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17673690 0.80 MAPT (0.77) LMNAMAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL18153389 0.80 ROCK2 (0.56) LMNAMAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL18063486 0.79 LMNA (0.54) LMNAMAPTSMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS LMNA 3744/4885MAPT 4486/4885SMN1; SMN2 4578/4885
US-10273228-B2 Hepatitis B viral assembly effectors HAVCR2, MAVS, HCCS LMNA 3744/4885MAPT 4486/4885SMN1; SMN2 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.